Goldman Sachs
MRVI icon

Goldman Sachs’s Maravai LifeSciences MRVI Stock Holding History

Goldman Sachs’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Sell
1,641,297
-379,032
-19% -$1.64M ﹤0.01% 3207
2026
Q1 		$5.72M Buy
2,020,329
+6,115
+0.3% +$20.7K ﹤0.01% 3571
2025
Q4 		$6.55M Buy
2,014,214
+442,059
+28% +$1.49M ﹤0.01% 3500
2025
Q3 		$4.51M Buy
1,572,155
+209,988
+15% +$536K ﹤0.01% 3739
2025
Q2 		$3.28M Sell
1,362,167
-52,705
-4% -$111K ﹤0.01% 3806
2025
Q1 		$3.13M Sell
1,414,872
-197,969
-12% -$782K ﹤0.01% 3802
2024
Q4 		$8.79M Sell
1,612,841
-425,707
-21% -$2.74M ﹤0.01% 2922
2024
Q3 		$16.9M Buy
2,038,548
+1,618,151
+385% +$14M ﹤0.01% 2211
2024
Q2 		$3.01M Buy
420,397
+221,130
+111% +$1.91M ﹤0.01% 3614
2024
Q1 		$1.73M Sell
199,267
-2,261
-1% -$15.3K ﹤0.01% 3967
2023
Q4 		$1.32M Sell
201,528
-39,774
-16% -$257K ﹤0.01% 4222
2023
Q3 		$2.41M Buy
241,302
+78,991
+49% +$867K ﹤0.01% 3623
2023
Q2 		$2.02M Sell
162,311
-215,542
-57% -$2.91M ﹤0.01% 3869
2023
Q1 		$5.29M Sell
377,853
-589,443
-61% -$8.47M ﹤0.01% 3014
2022
Q4 		$13.8M Buy
967,296
+587,745
+155% +$9.25M ﹤0.01% 2284
2022
Q3 		$9.69M Buy
379,551
+54,277
+17% +$1.36M ﹤0.01% 2535
2022
Q2 		$9.24M Buy
325,274
+41,846
+15% +$1.33M ﹤0.01% 2595
2022
Q1 		$10M Sell
283,428
-31,871
-10% -$1.07M ﹤0.01% 2695
2021
Q4 		$13.2M Buy
315,299
+195,439
+163% +$7.92M ﹤0.01% 2511
2021
Q3 		$5.88M Sell
119,860
-17,168
-13% -$837K ﹤0.01% 3219
2021
Q2 		$5.72M Buy
137,028
+6,800
+5% +$264K ﹤0.01% 3213
2021
Q1 		$4.64M Buy
130,228
+43,659
+50% +$1.45M ﹤0.01% 3201
2020
Q4 		$2.43M Buy
+86,569
New +$2.41M ﹤0.01% 3581

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Goldman Sachs's MRVI Position: Q2 2026 in Review

Goldman Sachs reduced its Maravai LifeSciences (MRVI) stake by 19% in Q2 2026, selling an estimated $1.64M and leaving 1,641,297 shares worth $10.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3207.

Goldman Sachs first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $16.9M in Q3 2024. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Goldman Sachs held 1,641,297 shares of Maravai LifeSciences worth $10.2M as of Q2 2026.
  • Goldman Sachs sold 379,032 Maravai LifeSciences shares in Q2 2026, an estimated $1.64M.
  • Maravai LifeSciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3207 holding.
  • Goldman Sachs first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Maravai LifeSciences position peaked at $16.9M in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.